Solid Biosciences SLDB 深 滬
等待開盤 07-24 09:30:00 美东时间
6.76
+0.530
+8.51%
華盛通- 最 高6.8476
- 今 開6.31
- 成交量 142.04万股
- 最 低 6.3041
- 昨 收 6.23
- 總市值 5.24亿
- 52周最高 10.37
- 市盈率 靜 --
- 換手率 1.83%
- 52周最低 2.41
- 委 比 -77.53%
- 總股本 7751.54万
- 歷史最高 822.60
- 量 比 0.62
- 振 幅 8.72%
- 歷史最低 1.81
- 每 手 1
- 風險率 2.73%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Solid Biosciences shares are trading higher after the company announced it received FDA Fast Track Designation status for SGT-501 gene therapy.
Solid Biosciences shares are trading higher after the company announced it rece...
07-23 22:46
Solid Biosciences to begin testing SGT-501 in U.S. and Canada
Solid Biosciences (NASDAQ:SLDB) said that the U.S. FDA and Health Canada has approved its gene therapy, SGT-501,for the treatment of heart disease caused by genetic disorder. The company expects to in...
07-09 21:36
Solid Biosciences Receives FDA IND And Health Canada CTA Approval For First-In-Class Cardiac Gene Therapy To Treat Catecholaminergic Polymorphic Ventricular Tachycardia
- SGT-501 is a novel gene therapy for rare, life-threatening, genetic arrhythmogenic disease with no approved therapies -- SGT-501 has received Orphan Drug Designation and Rare Pediatric Disease Designation from the FDA
07-09 04:08
美股大行评级 | 潜在涨幅61.27%！Loop Capital上调英伟达目标价至250美元，维持"买入"评级
今日重点评级关注：Benchmark：维持特斯拉(TSLA)"买入"评级，目标价从350美元升至475美元>>
06-27 08:37
Citigroup Initiates Coverage On Solid Biosciences with Buy Rating, Announces Price Target of $14
Citigroup analyst Yigal Nochomovitz initiates coverage on Solid Biosciences (NASDAQ:SLDB) with a Buy rating and announces Price Target of $14.
06-26 19:50
Analyst Downgrades Sarepta As Elevidys Safety Clouds Future Demand
Sarepta shares face pressure after a second Elevidys-linked death and analyst downgrade over safety concerns and lowered revenue prospects.
06-21 02:10
美股大行评级 | 潜在涨幅40%！华兴资本首予Coinbase买入评级，目标价353.3！Sarepta治疗遭多家机构下调评级和目标价！
美股大行评级 | 潜在涨幅40%！华兴资本首予Coinbase买入评级，目标价353.3！Sarepta治疗遭多家机构下调评级和目标价！
06-18 09:46
HC Wainwright & Co. Reiterates Buy on Solid Biosciences, Maintains $20 Price Target
HC Wainwright & Co. analyst Arthur He reiterates Solid Biosciences (NASDAQ:SLDB) with a Buy and maintains $20 price target.
06-17 19:09
Why Incyte Shares Are Trading Higher By Around 10%; Here Are 20 Stocks Moving Premarket
Shares of Incyte Corporation (NASDAQ:INCY) rose sharply in today's pre-market t...
06-16 18:00
美股大行评级 | 潜在涨幅925.64%！Aemetis获Ascendiant Capital升目标价至20美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1138028221594226688.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Ascendiant Capital：维持Aemetis(AMTX)"买入"评级，目标价从19美元升至20美元</p> <p>• Ascendiant Capital：维持Lucid Diagnostics(LUCD)"买
06-07 08:37
